Vol.

No.

October 27, 2023Oct 27, 2023

DOWNLOAD THE PDF

Cover Story

High-risk investments by ARPA-H aim to catalyze a new era in cancer research

The Advanced Research Projects Agency for Health is setting up a network of partners that would enable the federal government to fund and roll out new initiatives nationwide.

Conversation with The Cancer Letter

ARPA-H’s Renee Wegrzyn on cancer research: “Think big. Really big. I’m handing you a magic wand.”

By Matthew Bin Han Ong

Capitol Hill

Senate HELP Committee votes 15-6 to advance Bertagnolli’s confirmation as NIH director

By Alexandria Carolan

Free Letter To The Editor

“Field of Dread” (continued): Do “forever chemicals” in AstroTurf cause GBM?

Free In the Archives

Yale’s Richard Edelson on what got him started in research for cutaneous T-cell lymphoma

In Brief

Steven Rosenberg awarded National Medal of Technology and Innovation

Nadine Barrett named COE associate director at Atrium Health Wake Forest

Shelley Tworoger named head of oncological science, associate director for population science at OHSU Knight

Elad Sharon named clinical and translational director of Immunotherapy Toxicity Service at Dana-Farber

St. Jude, University of Cincinnati receive $4M from NCI to study immunotherapy in diffuse midline glioma

City of Hope raises $4.3M+ with music executive and entrepreneur Lyor Cohen

Fox Chase invests in Nucleus RadioPharma

UCI Health purchases GenesisCare radiation oncology centers in Orange County

Funding Opportunities

MIB Agents accepting applications for annual OutSmarting Osteosarcoma research grants

Clinical Roundup

COVID-19 pandemic associated with decline in number of reported cancer cases

Phase III CheckMate-67T trial of subcutaneous Opdivo + hyaluronidase meets endpoints in advanced or metastatic ccRCC

Imfinzi + chemo more than doubled pathologic CRR in gastric, gastroesophageal junction cancers

DUO-E phase III trial: Imfinzi + Lynparza reduces risk of progression/death vs. chemo in advanced/recurrent endometrial cancer

Phase III NATALEE trial: Kisqali demonstrates risk of recurrence in early breast cancer

Phase III PSMAfore trial: Pluvicto demonstrates clinically meaningful rPFS benefit in prostate cancer

Phase III ALINA study: Alecensa reduces risk of disease recurrence/death in NSCLC

UTSW: Emergency room visits by cancer patients can often be avoided

NCI-designated subspecialist reviews improve 94% of pancreatic cancer treatment paths

UC Davis researchers identify “switch” to activate cancer cell death

SWOG: Major pathologic response to neoadjuvant Keytruda in advanced melanoma trial exceeds 50%

Taletrectinib shrinks tumors in NSCLC indication in phase II trial

Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer

PFAS forever chemicals could be a risk factor in thyroid cancer, Mount Sinai researchers find

USC study reveals how exposure to racial discrimination can impact health care for Black cancer patients

Cedars-Sinai researchers find two potential treatments that improve outcomes in recurrent prostate cancer

Five-year monarchE outcome data demonstrate Verzenio’s long-term impact on cancer recurrence in high-risk early breast cancer

mRNA delivered by extracellular vesicles induces immunotherapy response in glioblastoma

Drugs & Targets

FDA approves Tibsovo for myelodysplastic syndromes

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues